Actively Recruiting
Observational Multicenter Study of Severe and Very Severe COPD Patients Across Brazil
Led by AstraZeneca · Updated on 2026-10-16
693
Participants Needed
10
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a prospective, observational multicenter study to understand severe and very severe COPD in Brazil. This study focuses on patients diagnosed by the GOLD 2024 criteria, considering that COPD severity is linked to exacerbation rates, disease progression, complications, and mortality. It aims to gather data from multiple regions of Brazil, each with different environmental exposures and population characteristics, to fill the gap in national information about this subgroup. Participants will be enrolled consecutively across eight hospitals representing Brazils five regions. The study involves no experimental treatment instead, it observes patients over 12 months with on-site visits at the start, 6 months, and 12 months, plus tele-consultations at 3 and 9 months. Data collected will focus on exacerbations, hospitalizations, mortality, and vaccination status, among other clinical details. Participants will undergo clinical assessments during visits and tele-consults, with data managed and reviewed by the study team. Researchers will measure outcomes such as hospitalizations, exacerbations, mortality, vaccination rates, and lung cancer incidence over approximately one year. The study is observational, so patient care continues as usual, and participant involvement lasts about 12 months.
CONDITIONS
Brief Title
Study That Will Evaluate the Brazilian Population With COPD.
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here